Back to Report Store Home

Global Cancer Supportive Care Therapeutics Market to 2022 – Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • Published: Mar-2017
  • Report Code: GBIHC434MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Cancer Supportive Care Market, Global, Key Marketed Products and Approved Indications, 2017 21

Figure 2: Cancer Supportive Care Market, Global, Annual Revenue for Neulasta ($bn), 2011–2022 23

Figure 3: Cancer Supportive Care Market, Global, Annual Revenue for Xgeva ($bn), 2011–2022 24

Figure 4: Cancer Supportive Care Market, Global, Annual Revenue for Aranesp for Amgen ($bn), 2006–2022 25

Figure 5: Cancer Supportive Care Market, Global, Annual Revenue for Nesp for Kyowa Hakko Kirin ($bn), 2011–2022 26

Figure 6: Cancer Supportive Care Market, Global, Annual Revenue for Xofigo ($bn), 2013–2022 27

Figure 7: Cancer Supportive Care Market, Global, Annual Revenue for Nucynta ($m), 2015–2022 28

Figure 8: Cancer Supportive Care Market, Global, Annual Revenue for Epogen ($bn), 2006-2022 30

Figure 9: Cancer Supportive Care Market, Global, Annual Revenue for Procrit ($bn), 2006–2022 30

Figure 10: Cancer Supportive Care Market, Global, Annual Revenue for Neupogen ($bn), 2011–2022 32

Figure 11: Cancer Supportive Care Market, Global, Annual Revenue for Aloxi ($m), 2011–2022 33

Figure 12: Cancer Supportive Care Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 35

Figure 13: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care by Stage of Development, Molecule Type and Program Type, 2017 36

Figure 14: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Indications by Stage of Development, 2017 37

Figure 15: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Indications by Molecule Type, 2017 38

Figure 16: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Therapies by Molecular Target, 2017 39

Figure 17: Cancer Supportive Care Market, Global, Pipeline for Key Cancer Supportive Care Indications by Molecular Target, 2017 40

Figure 18: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017 41

Figure 19: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017 42

Figure 20: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017 43

Figure 21: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017 44

Figure 22: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 45

Figure 23: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 46

Figure 24: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 47

Figure 25: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 48

Figure 26: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2017 49

Figure 27: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017 50

Figure 28: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017 51

Figure 29: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017 52

Figure 30: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2017 53

Figure 31: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2017 54

Figure 32: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017 55

Figure 33: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2017 56

Figure 34: Cancer Supportive Care Market, Global, Revenue for Tanezumab (Eli Lilly/Pfizer) ($m), 2018–2022 59

Figure 35: Cancer Supportive Care Market, Global, Revenue for Eflapegrastim ($m), 2018–2022 60

Figure 36: Cancer Supportive Care Market, Global, Market Size ($bn), 2015–2022 62

Figure 37: Cancer Supportive Care Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022 62

Figure 38: Cancer Supportive Care Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015–2022 64

Figure 39: Cancer Supportive Care Market, Global, Annual Revenue Forecast for drugs that’s target Cytokine receptors ($bn), 2015–2022 67

Figure 40: Cancer Supportive Care Market, Global, Annual Revenue Forecast for drugs that’s target GPCRs ($bn), 2015–2022 68

Figure 41: Cancer Supportive Care Market, Global, Company Analysis Matrix, 2015–2022 69

Figure 42: Cancer Supportive Care Market, Global, Cluster by Growth and Market Share, 2015–2022 70

Figure 43: Cancer Supportive Care Market, Global, Forecast Market Share by Company (%), 2015–2022 72

Figure 44: Cancer Supportive Care Market, Global, Companies by Compound Annual Growth Rate (%), Base year–2022 73

Figure 45: Cancer Supportive Care Market, Global, Revenue by Product Type, 2015–2022 74

Figure 46: Cancer Supportive Care Market, Global, Amgen Annual Revenue Forecast ($bn), 2015–2022 75

Figure 47: Cancer Supportive Care Market, Global, Bayer Annual Revenue Forecast ($m/$bn), 2015–2022 76

Figure 48: Cancer Supportive Care Market, Global, Heron Therapeutics Annual Revenue Forecast ($m/$bn), 2015–2022 77

Figure 49: Cancer Supportive Care Market, Global, Insys therapeutics Annual Revenue Forecast ($bn), 2015–2022 78

Figure 50: Cancer Supportive Care Market, Global, Kyowa Hakko Kirin, Annual Revenue Forecast ($m/$bn), 2015–2022 79

Figure 51: Cancer supportive Market, Global, Daiichi Sankyo, Annual Revenue Forecast ($bn), 2015–2022 80

Figure 52: Cancer Supportive Care Market, Late-Stage Developers by type, 2017 81

Figure 53: Cancer Supportive care Market, Global, Revenue by Product Type, 2015–2022 82

Figure 54: Cancer Supportive Care Market, Global, Proportion of Total Company Revenue Attributed to Cancer Supportive Care, 2015–2022 83

Figure 55: Cancer Supportive Care Market, Global, Licensing Deals by Region, Year and Value, 2006–2017 85

Figure 56: Cancer Supportive Care Market, Global, Licensing Deals by Indication and Value, 2006–2017 86

Figure 57: Cancer Supportive Care Market, Global, Licensing Deals by Stage of Development and Value, 2006–2017 87

Figure 58: Cancer Supportive Care Market, Global, Licensing Deals by Molecule Type and Target, 2006–2017 88

Figure 59: Cancer Supportive Care Market, Global, Co-development Deals by Region, Year and Value, 2006–2017 93

Figure 60: Cancer Supportive Care Market, Global, Co-development Deals by Indication, 2006–2017 94

Figure 61: Cancer Supportive Care Market, Global, Co-development Deals by Stage of Development and Value, 2006–2017 95

Figure 62: Cancer Supportive Care Market, Global, Co-development Deals by Molecule Type and Target, 2006–2017 96

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards